Connecting via Winsock to STN

Welcome to STN International! Enter x:x

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:21:18 ON 30 JUL 2009

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\11599002.str





chain nodes :
11 12 13 14 15
ring nodes :

1 2 3 4 5 6 7 8 9 10
chain bonds :
6-14 10-11 11-12 12-13 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
10-11 11-12 12-13 14-15
exact bonds :
6-14
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:N,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 11:22:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 68 TO ITERATE

100.0% PROCESSED 68 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          866 TO     1854
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> d scan

L2   2 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Quinoline, 3-(phenylsulfonyl)-8-[3-(1-piperidinyl)propoxy]-, hydrochloride
     (1:1)
MF   C23 H26 N2 O3 S . Cl H
```



● HCl

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l1 full
FULL SEARCH INITIATED 11:22:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1471 TO ITERATE

100.0% PROCESSED     1471 ITERATIONS                                30 ANSWERS
SEARCH TIME: 00.00.01

L3            30 SEA SSS FUL L1

=> file ca


=> s l3
L4            1 L3

=> d ibib abs fhitstr
```

L4 ANSWER 1 OF 1 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:386931 CA
TITLE: Preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders
INVENTOR(S): Ahmed, Mahmood; Johnson, Christopher Norbert; Miller, Neil Derek; Trani, Giancarlo; Witty, David R.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Witty, David R
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095346	A1	20051013	WO 2005-GB1106	20050324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730112	A1	20061213	EP 2005-729157	20050324
EP 1730112	B1	20080903		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007530648	T	20071101	JP 2007-505618	20050324
AT 407120	T	20080915	AT 2005-729157	20050324
ES 2313319	T3	20090301	ES 2005-729157	20050324
US 20070191345	A1	20070816	US 2006-599002	20060918

PRIORITY APPLN. INFO.: GB 2004-7025 A 20040329
WO 2005-GB1106 W 20050324
OTHER SOURCE(S): CASREACT 143:386931; MARPAT 143:386931
GI



I

AB The title compds. I [R1 = (un)substituted NH2 or a N containing heterocyclyl; X = a bond, (un)substituted CH2, (CH2)2, etc.; R2 = halo, CN, CF3, etc.; n = 0-3; R3, R4 = H, halo, CN, etc.; A = (un)substituted (hetero)aryl, arylaryl, etc.], useful in the treatment of CNS and other disorders, were prepared Thus, reacting 2-dimethylaminoethanol with 3-phenylsulfonyl-8-iodoquinoline (preparation given) afforded 48% I [R1 = NMe2; X = (CH2)2; R2-R4 = H; A = Ph] which was converted to its HCl salt which showed antagonist potency for the 5-HT6 receptor, having fpKi > 8.0 at human cloned 5-HT6 receptors. The pharmaceutical composition comprising the compound I is disclosed.

IT 866782-65-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders)

RN 866782-65-2 CA

CN Quinoline, 3-(phenylsulfonyl)-8-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	191.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'MARPAT' ENTERED AT 11:22:40 ON 30 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1961-PRESENT VOL 151 ISS 4 (20090724/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090149676 11 JUN 2009
DE 102007059214 10 JUN 2009
EP   2065708 03 JUN 2009
JP   2009137851 25 JUN 2009
WO   2009074534 18 JUN 2009
GB   2453808 22 APR 2009
FR   2924713 12 JUN 2009
RU   2357978 10 JUN 2009
CA   2643394 07 MAY 2009

The new MARPAT User Guide is now available at:
 http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s l3 full
FULL SEARCH INITIATED 11:22:45 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   8854 TO ITERATE

100.0% PROCESSED   8854 ITERATIONS   14 ANSWERS
SEARCH TIME: 00.00.04

L5   14 SEA SSS FUL L1

=> d ibib abs fqhit 1-14

L5   ANSWER 1 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 149:425659 MARPAT
TITLE: Preparation of phenylnaphthalenols and related
                         compounds as (17)β-hydroxy steroid dehydrogenase
                         inhibitors
INVENTOR(S):   Hartmann, Rolf; Frotscher, Martin; Oberwinkler,
                         Sandrine; Ziegler, Erika; Messinger, Josef; Thole,
                         Heinrich-Hubert
PATENT ASSIGNEE(S):   Universitaet des Saarlandes, Germany
SOURCE: PCT Int. Appl., 125pp.
                         CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008116920	A2	20081002	WO 2008-EP53672	20080327
WO 2008116920	A3	20090402		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

DE 102007015169 A1 20081002 DE 2007-102007015169 20070327
PRIORITY APPLN. INFO.: DE 2007-102007015169 20070327

GI



I



II

AB Title compds. I [W, X, Y, Z = C=, N=; R1 = H, halo, OH, etc.; R2 = H, halo, OH, etc.; R3 = H, halo, OH, etc.; R4 = H, OH; R5 = H, halo, OH, etc.; R6 = H, halo, OH, etc.; R7 = H, halo, OH, etc.; R8 = H, halo, OH, etc. R9 = H, OH, CN, etc.; R10 = H, OH, CN, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, Suzuki coupling of 6-bromo-2-naththol and phenylboroic acid afforded claimed phenylnaphthalenol II in 87% yield. In (17)β-hydroxysteroid dehydrogenase 1 inhibition assays, 17-examples of compds. I exhibited IC50 values ranging from 7-840 nM.

MSTR 1

G4—G19

G4 = 45

G12—G10
45

G5 = bond
G10 = heteroaryl <containing up to 12 atoms,
1 or more heteroatoms, zero or more N, zero or more O,
zero or more S (no other heteroatoms)> (opt. substd.) / Ph
G12 = SO2
G19 = 7



G22 = 108 / 115



G32 = 268 / N



Patent location: claim 1
Note: and pharmacologically acceptable salts
Note: substitution is restricted
Note: also incorporates claim 11

L5 ANSWER 2 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 148:419118 MARPAT
TITLE: Measurement of rate of light-induced change of dye optical property in presence of probe-target hybrids for detecting polynucleotides
INVENTOR(S): Bupp, Charles Robert; Choi, K. Yeon; Koshinsky, Heather; Nulf, Christopher; Urdea, Mickey; Wang, Miaomiao; Zwick, Michael
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 66pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080096193	A1	20080424	US 2006-362359	20061024

PRIORITY APPLN. INFO.: US 2006-362359 20061024

AB Methods of determining the presence or amount of a target polynucleotide in a sample are provided. A sample that contains a target polynucleotide, a nucleic acid analog that is complementary to a target nucleic acid sequence of the target polynucleotide, and a cyanine dye for which the rate of change in an optical property is different in the presence and absence of a target polynucleotide/nucleic acid analog hybrid are combined to produce a reaction mixture The rate of change in an optical property of the dye in the reaction mixture is compared to a reference value characteristic of the rate of change in the optical property of the dye in a similar reaction mixture containing a known amount of a polynucleotide/nucleic acid analog

hybrid to determine a relative rate of change in the optical property. The relative rate of change in the optical property of dye in the reaction mixture is correlated with the presence or amount of the specified target polynucleotide in the sample.

MSTR 1



G1 = 31 / 33 / 38

G10—G6 (31) G7—G10—G19 (33) G9—G22 (38)

G3 = 58 / 60 / 65

G10—G17 (58) G18—G10—G20 (60) G9—G22 (65)

G4 = bond
G5 = 54-17 55-19



G9 = SO2
G10 = O
G11 = heteroaryl <containing 1 or more heteroatoms,
zero or more N, zero or more O,
zero or more S (no other heteroatoms), mono- or bicyclic>
G17 = carbon chain <containing 1-9 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G11)
G22 = Ph (opt. substd.)
Patent location: claim 1
Note: or salts or esters
Note: additional interruption also claimed
Note: substitution is restricted

L5 ANSWER 3 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 147:358263 MARPAT
TITLE: Carbocyanine dye dimers linked by a conjugated alkenyl chain for use in detection of nucleic acid

hybridization

INVENTOR(S): Bupp, Charles R., II; Choi, K. Yeon; Holmes-Davis, Rachel Anne; Izmailov, Alexander; Koshinsky, Heather; Nulf, Christopher J.; Urdea, Micky; Wang, Miaomiao; Warner, Brian David; Zwick, Michael
PATENT ASSIGNEE(S): Investigen, Inc., USA
SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007100711	A2	20070907	WO 2007-US4814	20070223
WO 2007100711	A3	20090409		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070231821	A1	20071004	US 2007-710667	20070223
EP 2010677	A2	20090107	EP 2007-751566	20070223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2006-776595P 20060224
WO 2007-US4814 20070223

AB Dimeric carbocyanine dyes linked by a conjugated alkenyl moiety that change optical properties upon binding nucleic acids are described for use in quant. hybridization assays. The dyes can be used as reporters in assays using nucleic acid probes, or with analogs such as peptide nucleic acids or locked nucleic acids as probes. The rate of change in an optical property of the dye in the hybridization is compared to a reference value characteristic of the rate of change in the optical property of the dye in a similar reaction mixture containing a known quantity of a to determine a relative rate of change in the optical property. The relative rate of change in the optical property of dye in the reaction mixture is correlated with the presence or amount of the specified target polynucleotide in the sample. The dyes are hydrophobic and a detergent is necessary for their solubilization. Optimization of assay conditions and the determination of sensitivities of assays using different conditions, probe types, light sources and analyte sequence concns. are reported.

MSTR 1



G1 = 31 / 33 / 38

G10—G6 (31) G7—G10—G19 (33) G9—G22 (38)

G3 = 58 / 60 / 65

G10—G17 (58) G18—G10—G20 (60) G9—G22 (65)

G4 = bond
G5 = 54-17 55-19



G9 = SO2
G10 = O
G11 = heteroaryl <containing 1 or more heteroatoms,
zero or more N, zero or more O,
zero or more S (no other heteroatoms), mono- or bicyclic>
G17 = carbon chain <containing 1-9 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G11)
G22 = Ph (opt. substd.)
Patent location: claim 1
Note: or salts or esters
Note: additional interruption also claimed
Note: substitution is restricted

L5 ANSWER 4 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 146:358716 MARPAT
TITLE: Preparation of alkyl sulfoxide quinolines as Nk-3 receptor ligands
INVENTOR(S): Albert, Jeffrey S.; Koether, Gerard M.; Alhambra, Cristobal; Kang, James; Simpson, Thomas R.; Woods, James; Li, Yan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007035158	A1	20070329	WO 2006-SE1068	20060919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006292849	A1	20070329	AU 2006-292849	20060919
CA 2621062	A1	20070329	CA 2006-2621062	20060919
EP 1928835	A1	20080611	EP 2006-784189	20060919
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009508946	T	20090305	JP 2008-532190	20060919
MX 2008003765	A	20080402	MX 2008-3765	20080318
KR 2008046669	A	20080527	KR 2008-706742	20080320
IN 2008DN02393	A	20080725	IN 2008-DN2393	20080320
NO 2008001862	A	20080616	NO 2008-1862	20080417
US 20080214605	A1	20080904	US 2008-67572	20080421
CN 101312950	A	20081126	CN 2006-80043132	20080519

PRIORITY APPLN. INFO.:
US 2005-719275P 20050921
US 2005-719286P 20050921
WO 2006-SE1068 20060919

GI



I II

AB Title compds. represented by the formula I [wherein R1 = H, (cyclo)alkyl or alkyl-OCO-; A = Ph or cycloalkyl; R2, R3 = independently H, OH, NH2, etc.; n = 1-3; R4 = E-SOr-(CH2)p-; E = (cyclo)alkyl or (hetero)aryl; p = 0-6; r = 0-2; R5 = independently H, halo, amino, etc.; q = 1-3; and

stereoisomer, enantiomer, in vivo-hydrolyzable precursor or pharmaceutically acceptable salts thereof] were prepared as NK-3 receptor ligands. For example, amidation of 3-(methylthio)-2-phenylquinoline-4-carboxylic acid with ((S)-(-)-1-phenylpropyl)amine gave II in 70% yield. The biol. test for NK-3 receptor binding activity was described (no data). I and their pharmaceutical compns. are useful for the treatment or prophylaxis of a disease or condition in which modulation of the NK-3 receptor is beneficial, such as mental and behavioral disorders (no data).

MSTR 1



G4 = 51 / 299

G12—G13—G14 G13—G15
51 299

G5 = 75

G18—G9
75

G9 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G10)
G10 = NH2
G12 = (0-6) CH2
G13 = SO2
G14 = 4-pyridyl
G18 = O
Patent location: claim 1
Note: or in vivo hydrolysable precursors or pharmaceutically acceptable salts
Stereochemistry: or stereoisomers or enantiomers

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 145:377221 MARPAT
TITLE: Preparation of dihydro pyridines, quinolines, and

isoquinolines as anti-Alzheimer agents.
INVENTOR(S): Marsais, Francis; Bohn, Pierre; Levacher, Vincent; Le Fur, Nicolas
PATENT ASSIGNEE(S): Insa Rouen, Fr.; Gous Inc.
SOURCE: PCT Int. Appl., 136pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103120	A2	20061005	WO 2006-EP3787	20060329
WO 2006103120	A3	20070215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1731507	A1	20061213	EP 2005-290914	20050426
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
AU 2006228683	A1	20061005	AU 2006-228683	20060329
CA 2603345	A1	20061005	CA 2006-2603345	20060329
EP 1868998	A2	20071226	EP 2006-742673	20060329
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN07518	A	20071109	IN 2007-DN7518	20070928
US 20090062279	A1	20090305	US 2008-909911	20080716

PRIORITY APPLN. INFO.: EP 2005-290719 20050401
EP 2005-290914 20050426
WO 2006-EP3787 20060329

OTHER SOURCE(S): CASREACT 145:377221
GI



I

AB Title compds. [I; dotted lines = double bond between CR5-CR6, and another double bond between either CR2CR3 or CR3CR4; R1-R6 = H, OH, alkyl, aryl,

heteroaryl, aralkyl, alkylaryl, alkoxy, hydroxyalkyl, alkoxyalkyl, Ph, (CH2)nCO2H, Z, Z1; R4R5, R5R6 = atoms to form (substituted) 6-membered aryl, 5-6 membered heterocyclyl; ≥1 of R2, R3, R5 = CO2R, COSR, CONRR', cyano, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halo, heteroaryl; R, R' = H, alkyl, cycloalkyl, aminoalkyl, aryl,, heteroaryl, etc.; NRR' = (substituted) heterocyclyl; Z = LmZ1; L = alkyl, aryl, heteroaryl, Ph, alkylaryl, aralkyl; Z1 = XC(:Y)NR7R8; X, Y = O, S; R7, R8 = H, alkyl, aryl, heteroaryl, aralkyl, Ph, cyclopropyl, (CH2)nCO2H; n = 1-6; with a proviso], were prepared Thus, Et 1-methyl-7-N,N-dimethylcarbamoyloxy-1,4-dihydroquinoline-3-carboxylate (5-step preparation from 3-cyano-7-methoxyquinoline given) inhibited human acetylcholinesterase with IC50 = 0.5 μM.

MSTR 1



G1 = 5



G2 = 289-2 290-3 288-4 282-6 287-7



G3 = N
G4 = 39



G11 = SO2
G12 = 169

169 

G13 = O
G14 = NH2
G17 = 166

166 G11—G12

G34 = 339

339 G11—G12

Patent location: claim 1
Note: G9 is optionally present
Note: substitution is restricted
Note: or pharmaceutically acceptable salts
Note: also incorporates claim 2, structure G+ and claim 40, structures E1, E2, and E3
Stereochemistry: or stereoisomers

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 144:88181 MARPAT
TITLE: Heteroaryl sulfones and sulfonamides and the preparation, pharmaceutical compositions, and therapeutic uses thereof, particularly for treatment of proliferative diseases such as cancer
INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.
PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123077	A2	20051229	WO 2005-US20023	20050608
WO 2005123077	A3	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005253966	A1	20051229	AU 2005-253966	20050608
CA 2569705	A1	20051229	CA 2005-2569705	20050608
EP 1765804	A2	20070328	EP 2005-763374	20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008501804	T	20080124	JP 2007-527659	20050608
IN 2006DN07044	A	20070713	IN 2006-DN7044	20061123
US 20070232649	A1	20071004	US 2006-628019	20061128
MX 2006014230	A	20070214	MX 2006-14230	20061206
KR 2007034574	A	20070328	KR 2007-700456	20070108

PRIORITY APPLN. INFO.: US 2004-578162P 20040608
WO 2005-US20023 20050608

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein: R1 = halo, hydrocarbyl, acyl, various disubstituted amino or substituted hydroxy derivs., NO2, cyano, PO3H2 diesters, mono- or disubstituted SO2NH2, guanidino or monohydrocarbyl derivs., haloalkyl, or heteroalkyl; R2 = (un)substituted (hetero)aryl; M = bond, NR3, CH:CH, CHR4, CH(R4)A(CH:CH)m; N(R3)A(CH:CH)m; R3, R4 = H, alkyl; A = SO2, CO; Q = O, S, or NH; n = 0-4; m = 0-1; with provisos; including salts] are disclosed. I are useful as antiproliferative agents including, for example, as anticancer agents. Examples include approx. 60 prepared compds. I and 2 bioassays. Over 350 invention compds. are also named in claims. For instance, cyclocondensation of 5-bromosalicylaldehyde with [(4-methoxyanilino)sulfonyl]acetic acid in refluxing AcOH in the presence of PhCH2NH2 gave invention compound II. In tests against 5 human tumor cell lines, invention compound III had 50% growth-inhibitory concns. (IG50) of 12-16 μM.

MSTR 1



G1 = O / NH
G2 = 199



G4 = 8



G24 = 123



G32 = alkylene <containing 2-6 C>
Patent location: claim 1
Note: additional ring formation also claimed
Note: substitution is restricted
Note: or salts
Note: also incorporates claim 47 and 48

L5 ANSWER 7 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:386931 MARPAT
TITLE: Preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders
INVENTOR(S): Ahmed, Mahmood; Johnson, Christopher Norbert; Miller, Neil Derek; Trani, Giancarlo; Witty, David R.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Witty, David R
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095346	A1	20051013	WO 2005-GB1106	20050324

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
EP 1730112 A1 20061213 EP 2005-729157 20050324
EP 1730112 B1 20080903
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
JP 2007530648 T 20071101 JP 2007-505618 20050324
AT 407120 T 20080915 AT 2005-729157 20050324
ES 2313319 T3 20090301 ES 2005-729157 20050324
US 20070191345 A1 20070816 US 2006-599002 20060918
PRIORITY APPLN. INFO.: GB 2004-7025 20040329
WO 2005-GB1106 20050324
OTHER SOURCE(S): CASREACT 143:386931
GI



I

AB The title compds. I [R1 = (un)substituted NH2 or a N containing heterocyclyl; X = a bond, (un)substituted CH2, (CH2)2, etc.; R2 = halo, CN, CF3, etc.; n = 0-3; R3, R4 = H, halo, CN, etc.; A = (un)substituted (hetero)aryl, arylaryl, etc.], useful in the treatment of CNS and other disorders, were prepared Thus, reacting 2-dimethylaminoethanol with 3-phenylsulfonyl-8-iodoquinoline (preparation given) afforded 48% I [R1 = NMe2; X = (CH2)2; R2-R4 = H; A = Ph] which was converted to its HCl salt which showed antagonist potency for the 5-HT6 receptor, having fpKi > 8.0 at human cloned 5-HT6 receptors. The pharmaceutical composition comprising the compound I is disclosed.

MSTR 1



G1 = G5
G2 = NH2

G5 = (1-3) 14



G8 = Ph
G25 = 200



Patent location: claim 1

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 139:265380 MARPAT
TITLE: Hair dye compositions containing quinolinium salts
INVENTOR(S): Sauter, Guido; Braun, Hans-Juergen; Duc-Reichlin, Nadia
PATENT ASSIGNEE(S): Wella Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1346719	A1	20030924	EP 2002-25423	20021115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
DE 10211413	A1	20030925	DE 2002-10211413	20020315
US 20030177592	A1	20030925	US 2003-361380	20030210
US 6977001	B2	20051220		
BR 2003000496	A	20040810	BR 2003-496	20030313

PRIORITY APPLN. INFO.: DE 2002-10211413 20020315

AB The invention concerns hair dyes that are prepared from two components; component A1 contains a quinolinium derivative; component A2 includes a nucleophile compound Other direct dyes can be added; solns., emulsions, creams, foams, gels can be formulated. Thus component A1 contained (g): 4-chloro-1-ethylquinolinium tetrafluoroborate 0.70 decyl glycoside 4.0; EDTA disodium salt 0.2; ethanol 5.0; water to 100. Component A2 included: 1,4-diaminobenzene 0.27; decyl glycoside 4.0; EDTA disodium salt 0.2; ethanol 5.0; 25% ammonia solution 6.0; water to 100.

MSTR 1



G2 = 27 / 52



G3 = tolyl
G5 = heteroaryl (opt. substd.)
G7 = O
G14 = SO2
Patent location: claim 1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 138:271682 MARPAT
TITLE: Preparation of cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme for treatment of inflammatory disorders
INVENTOR(S): Ott, Gregory; Chen, Xiao-Tao; Duan, Jingwu; Lu, Zhonghui
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024899	A2	20030327	WO 2002-US29685	20020916
WO 2003024899	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002341715	A1	20030401	AU 2002-341715	20020916
US 20030139388	A1	20030724	US 2002-244626	20020916
US 6740649	B2	20040525		
EP 1427408	A2	20040616	EP 2002-775865	20020916

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: US 2001-322630P 20010917
WO 2002-US29685 20020916

GI



I



II

AB Title compds. I [wherein ring B = (un)substituted 4-7 membered (hetero)cyclic ring containing 0-2 O, N, NR1, or SOp atoms and 0-3 carbonyl groups; R1 and R2 = independently Q, alk(en/yn)ylene-Q, or (un)substituted alkylene-Q interrupted by O, NRa, CO, CO2, CONRa, NRaCO, NRaCO2, NRaCONRa, SOp, NRaSO2, or SO2NRa; or R1 = (un)substituted alkylene-Q interrupted by OCO, OCO2, or OCONRa; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1, Cl, F, alk(en/yn)ylene-Q1, or (un)substituted alkylene-Q1 interrupted by O, NR1, NRaCO, CONRa, CO, CO2, SOp, or SO2NRa; Q1 = H or (un)substituted Ph, naphthyl, or heterocyclyl; Za = (un)substituted benzimidazolyl, indolyl, imidazopyridinyl, pyrazolylpyridinyl, benzofuranyl, benzothiazinyl, quinolinyl, etc.; Ra = independently H, alkyl, Ph, or benzyl; p = 0-2; or stereoisomers or pharmaceutically acceptable salts thereof] were prepared as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof. For example, reaction of benzyl Me maleate with paraformaldehyde and glycine gave benzyl Me (cis)-3,4-pyrrolidinedicarboxlyate (100%). BOC-protection (64%), debenzylation (96%), resolution of the (3S,4S)-isomer with (S)-α-methylbenzylamine, conversion to the carbamate with DPPA and PhCH2OH (76%), and Pd catalyzed hydrogenation (100%) provided Me (3S,4S)-4-amino-1-(tert-butoxycarbonyl)-3-pyrrolidinecarboxylate. Coupling of the amine with 4-[(2-methylthio-1H-benzimidazol-1-yl)methyl]benzoic acid (preparation given) afforded the amide (99%), which was treated with NH2OH•HCl/MeONa to give the hydroxamic acid (3S,4S)-II

(33%). A number of the compds. of the invention inhibited MMP-1, 2, 3, 7, 8, 9, 10, 12, 13, 14, 15, and/or 16 with Ki values of ≤ 10 μM. Thus, I are useful for the treatment of a wide variety of inflammatory disorders (no data).

MSTR 1



G3 = 16



G5 = 80-13 78-44 81-17 82-20



G11 = 111



G14 = Ph
G15 = SO2
G17 = O
G19 = C(O)
G29 = 212 / 227



Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted
Note: additional ring formation also claimed
Stereochemistry: or stereoisomers

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 138:78134 MARPAT
TITLE: Direct hair dyes composed of 1-benzopyrane-derivatives and an electrophilic substance
INVENTOR(S): Sauter, Guido; Braun, Hans-Juergen; Brouillard, Raymond; Fougerousse, Andre; Roehri-Stoeckel, Christine
PATENT ASSIGNEE(S): Wella Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000214	A1	20030103	WO 2002-EP1194	20020206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10130144	A1	20030102	DE 2001-10130144	20010622
AU 2002246084	A1	20030108	AU 2002-246084	20020206
BR 2002005662	A	20030715	BR 2002-5662	20020206
EP 1404289	A1	20040407	EP 2002-714147	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521144	T	20040715	JP 2003-506861	20020206
US 20030196281	A1	20031023	US 2003-380896	20030320
PRIORITY APPLN. INFO.:			DE 2001-10130144	20010622
			WO 2002-EP1194	20020206

AB The invention concerns a two component hair dye where the components are mixed in the presence of acids or bases if required to form a direct dye that can be removed with sulfite-containing reducing agents if required. The first component includes 1-benzopyrane-derivs.; the second component contains an electrophilic substance that is selected from the group of carbonyls, imines and 1-alkyl-quinoline derivs. Thus a first components was composed of (g): 7-hydroxy-4-methyl-2-phenyl-1-benzylpyrylium chloride 3.14; cetylstearyl alc. 12.0; Brij 78 P 2.8; ethanol 24.8; water to 100. The second component was a mixture of (g): 4-hydroxy-3-methoxy-benzaldehyde 1.75; cetylstearyl alc. 12.0; Brij 78 P 2.8; ethanol 24.8; water to 100.

MSTR 2

G1—G3 G10

G1 = 10



G3 = 47 / 68



G4 = heteroaryl (opt. substd.)
G5 = tolyl
Patent location: claim 1

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 134:17502 MARPAT
TITLE: Preparation of phenoxypropylamine compounds as antagonists of 5-HT1A receptor
INVENTOR(S): Nishiyama, Akira; Bougauchi, Masahiro; Kuroita, Takanobu; Minoguchi, Masanori; Morio, Yasunori; Kanzaki, Kouji
PATENT ASSIGNEE(S): Welfide Corp., Japan
SOURCE: PCT Int. Appl., 335 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071517	A1	20001130	WO 2000-JP3279	20000522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375008	A1	20001130	CA 2000-2375008	20000522
BR 2000011542	A	20020305	BR 2000-11542	20000522
EP 1188747	A1	20020320	EP 2000-927844	20000522
EP 1188747	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2002001540	A2	20020828	HU 2002-1540	20000522

HU 2002001540	A3	20021228		
NZ 516111	A	20030530	NZ 2000-516111	20000522
CN 1164574	C	20040901	CN 2000-808604	20000522
AU 777594	B2	20041021	AU 2000-46160	20000522
AT 303987	T	20050915	AT 2000-927844	20000522
ES 2244438	T3	20051216	ES 2000-927844	20000522
IL 146564	A	20061231	IL 2000-146564	20000522
JP 3893878	B2	20070314	JP 2000-619774	20000522
US 20020111358	A1	20020815	US 2001-990389	20011123
US 6720320	B2	20040413		
MX 2001012046	A	20030904	MX 2001-12046	20011123
KR 799134	B1	20080129	KR 2001-715024	20011123
ZA 2001010137	A	20030225	ZA 2001-10137	20011210
US 20040138227	A1	20040715	US 2003-740418	20031222
US 7196199	B2	20070327		
KR 2007118193	A	20071213	KR 2007-726625	20071115
KR 882544	B1	20090212		

PRIORITY APPLN. INFO.:

JP 1999-142750	19990524
JP 1999-166160	19990614
JP 1999-277384	19990929
JP 2000-18080	20000125
WO 2000-JP3279	20000522
KR 2001-715024	20011123
US 2001-990389	20011123

GI



I

AB Phenoxypropylamine compds. represented by general formula [I; a bond represented by a solid and a dotted line is a double or single bond; X = H, HO, C1-8 alkoxy, acyloxy, oxo; R1 = 4-substituted piperidino, piperazino, 1-piperidinylamino, or 1,2,3,6-tetrahydropyrazinyl, (un)substituted aryloxy- or arylthioamino, (un)substituted heterocyclyloxy- or heterocyclylthioamino, etc.; R3 = H, C1-18 alkyl, halo; Ra, Rb, Rc = H, C1-18 alkyl, OH, C1-8 alkoxy, halo, acyl, NO2, NH2], optically active isomers thereof or pharmaceutically acceptable salts thereof and hydrates of the same are prepared These compds. have an affinity selectively for 5-HT1A receptor, simultaneously show an antagonistic activity, and inhibit the reuptake of 5-HT, thereby being usable as antidepressant agents quickly achieving an antidepressant effect (no data). Thus, 4-(3,4-dichlorophenyl)piperazine was added to a solution of (S)-5-(4-glycidyloxybenzo[b]furan-2-yl)-3-methylisoxazole in MeOH and refluxed for 8 h to give (S)-1-(4-(3,4-dichlorophenyl)piperazin-1-yl)-3-(2-(3-methylisoxazol-5-yl)benzo[b]furan-4-yloxy)-2-propanol.

MSTR 1A



G3 = 26



G4 = 3



G12 = 176-3 183-1



G14 = 73



G16 = C(O)
G18 = 75



G19 = SO2
G20 = 83



Patent location: claim 1

Note: and pharmacologically acceptable salts or hydrates

REFERENCE COUNT: 151 THERE ARE 151 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 133:89542 MARPAT
TITLE: Preparation of quinoxalines as non-peptide GLP-1 agonists
INVENTOR(S): Teng, Min; Truesdale, Larry Kenneth; Bhumralkar, Dilip; Kiel, Dan; Johnson, Michael D.; Thomas, Christine; Jorgensen, Anker Steen; Madsen, Peter; Olesen, Preben Houlberg; Knudsen, Liselotte Bjerre; Petterson, Ingrid Vivika; Cornelis De Jong, Johannes; Behrens, Carsten; Kodra, Janos Tibor; Lau, Jesper
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042026	A1	20000720	WO 2000-DK14	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1147094	A1	20011024	EP 2000-900499	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534512	T	20021015	JP 2000-593594	20000114
US 6927214	B1	20050809	US 2000-483504	20000114
PRIORITY APPLN. INFO.:			DK 1999-41	19990115
			US 1999-116116P	19990115
			WO 2000-DK14	20000114

GI



I

AB The title compds. I [R1, R2, R3, R4 independently = H, halogen, CN, CF3, NO2, OR5, lower alkyl, SR5, S(O2)NR5R6, etc (a proviso is given); A, B = H, halogen, OH, CF3, CF2CF3, CN, NO2, alkyl, alkenyl, etc; L, M = (CH2)mS(CH2)n, (CH2)mO(CH2)n, (CH2)mS(O)(CH2)n, (CH2)mS(O)2(CH2)n, etc; X, V = :N or :CD; D = H, halogen, CN, CF3, NO2, etc; m, n independently = 0, 1, 2, 3, or 4] useful as non-peptide GLP-1 agonists for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as Type 1 diabetes, Type 2 diabetes and obesity (no data), are prepared Formulations are given.

MSTR 1



G1 = 15 / 17 / 29 / 34

G2 = alkyl <containing 1-6 C>
(substd. by heterocycle <containing 3-10 atoms, 1 or more heteroatoms, zero or more N, zero or more O, zero or more S (no other heteroatoms), non-aromatic, 0 or more double-exact bonds> (opt. substd.))
G3 = O
G5 = 19



G7 = 1 or more N / 23



G13 = 42



G14 = SO2
G15 = 203



Patent location: claim 1

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 120:191707 MARPAT
TITLE: 2-Substituted saccharin derivative proteolytic enzyme inhibitors
INVENTOR(S): Hlasta, Dennis John; Desai, Ranjit Chimanlal; Subramanyam, Chakrapani; Lodge, Eric Piatt; Dunlap, Richard Paul; Boaz, Neil Warren; Mura, Albert Joseph; Latimer, Lee Hamilton
PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
SOURCE: Eur. Pat. Appl., 77 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 542372	A1	19930519	EP 1992-203469	19921112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5236917	A	19930817	US 1991-793033	19911115
AU 9225340	A	19930520	AU 1992-25340	19920925
AU 654581	B2	19941110		
CA 2079822	A1	19930516	CA 1992-2079822	19921005
NO 9204401	A	19930518	NO 1992-4401	19921113
NO 303119	B1	19980602		
HU 66873	A2	19950130	HU 1992-3566	19921113
IL 103748	A	19970218	IL 1992-103748	19921113
RU 2101281	C1	19980110	RU 1992-4381	19921113
JP 05194444	A	19930803	JP 1992-305295	19921116
US 5371074	A	19941206	US 1993-67637	19930524
US 5650422	A	19970722	US 1994-270964	19940705
US 5596012	A	19970121	US 1995-449152	19950524
US 5874432	A	19990223	US 1997-803297	19970220

PRIORITY APPLN. INFO.:
US 1991-793033 19911115
US 1989-347125 19890504
US 1989-347126 19890504
US 1990-514920 19900426
US 1993-67637 19930524
US 1994-270964 19940705

GI



I

AB The title compds. I [L = O, S, SO, SO2; R1 = (un)substituted Ph, (un)substituted heterocyclyl, etc.; R2 = H, lower alkoxycarbonyl, Ph, PhS; R3 = H, halogen, (un)substituted alkyl, Ph, lower alkoxy, lower alkoxycarbonyl, CN, etc.; R4 = H or 1-3 substituents selected from halogen, CN, NO2, NH2, etc.; m, n = 0, 1; when m = 0 then R1 can only be heterocyclyl and CHR2 can only be bonded to a ring N of R1; when m = 0, n = 1 and L is O, S, or SO, then R2-R4 = H; when m = 0, n = 1, L is S, R2, R4 = H and R3 = halogen; when m = 0, n = 1, and L is SO or SO2 then R2 is lower alkoxycarbonyl and R3 = R4 = H while R1 ≠ substituted Ph], useful for the treatment of degenerative diseases (no data), are prepared Thus, 2-hydroxymethyl-4-chlorosaccharin was reacted with thionyl chloride, producing 2-chloromethyl-4-chlorosaccharin (II). II demonstrated inhibition constant for human leukocyte elastase (rate of reactivation of enzyme to rate of inactivation of enzyme) of 0.5 nM and 26 nM for α-chymotrypsin.

MSTR 1A



G1 = O
G2 = bond
G3 = 163



G12 = 81



G13 = phenylene
Patent location: claim 1

Note: substitution is restricted

L5 ANSWER 14 OF 14 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 119:213908 MARPAT
TITLE: Silver halide photographic material
INVENTOR(S): Fukuwa, Junichi; Kobayashi, Akira; Goto, Kenji
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Can. Pat. Appl., 71 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2065106	A1	19921005	CA 1992-2065106	19920403
JP 05197057	A	19930806	JP 1992-110787	19920403

PRIORITY APPLN. INFO.: JP 1991-99626 19910404
GI



I

AB A Ag halide photog. material for high-contrast dot image formation is disclosed. The material comprises a support and provided thereon a Ag halide emulsion layer and layers adjacent to the emulsion layer. The emulsion is subjected to desalinization comprising using denatured gelatin in the process of preparation thereof. At least one of the layers contains a hydrazine derivative and a compound selected from the group consisting of those represented by formulas A(CH2)nSC(:N+HR1)NHR1 X- (A = OH, SO3-, or N(R2)2; R1 = H, (substituted) alkyl having 1-5 C atoms, or (substituted) Ph; R2 = (substituted) alkyl having 1-5 C atoms; X- = an anion), (R3)2N(CH2)nSC(S)N(R4)2 (R3 = H, (substituted) alkyl having 1-5 C atoms, or (substituted) aryl; R4 = (substituted) alkyl having 1-5 C atoms or (substituted) Ph; n = an integer of 2-5), or I (Q = a group of atoms necessary to form a 5- or 6-membered heterocyclic ring which may be condensed with a benzene or heterocyclic ring; M = H, an alkali metal atom, an ammonium group, or an amine residue).

MSTR 3B

G1—G2

G1 = 232



G7 = SO2Ph / 43



Patent location: claim 1

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\12599002.str





chain nodes :
11 12 13 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
6-12 10-11 11-16 12-13 16-17
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
10-11 11-16 12-13 16-17
exact bonds :
6-12
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:N,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 16:Atom 17:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 N,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l6 sam
SAMPLE SEARCH INITIATED 11:24:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 289 TO ITERATE

100.0% PROCESSED 289 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4761 TO 6799
PROJECTED ANSWERS: 1 TO 80

L7 1 SEA SSS SAM L6

=> d scan

L7 1 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Furanamine, tetrahydro-4-[[3-(phenylsulfonyl)-8-quinolinyl]oxy]-, hydrochloride (1:1), (3S,4R)-
MF C19 H18 N2 O4 S . Cl H

Absolute stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

=> s l6 full
FULL SEARCH INITIATED 11:24:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5502 TO ITERATE

100.0% PROCESSED 5502 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.02

L8 4 SEA SSS FUL L6

=> file ca

=> s l8
L9 1 L8

=> d ibib

L9 ANSWER 1 OF 1 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:386931 CA
TITLE: Preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders
INVENTOR(S): Ahmed, Mahmood; Johnson, Christopher Norbert; Miller, Neil Derek; Trani, Giancarlo; Witty, David R.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Witty, David R
SOURCE: PCT Int. Appl., 34 pp.

```
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 2005095346         A1    20051013    WO 2005-GB1106         20050324
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1730112            A1    20061213    EP 2005-729157         20050324
     EP 1730112            B1    20080903
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
     JP 2007530648         T     20071101    JP 2007-505618         20050324
     AT 407120             T     20080915    AT 2005-729157         20050324
     ES 2313319            T3    20090301    ES 2005-729157         20050324
     US 20070191345        A1    20070816    US 2006-599002         20060918
PRIORITY APPLN. INFO.:                       GB 2004-7025        A  20040329
                                             WO 2005-GB1106      W  20050324
OTHER SOURCE(S):          CASREACT 143:386931; MARPAT 143:386931
OS.CITING REF COUNT:      3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
                                (3 CITINGS)
REFERENCE COUNT:          7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 11:21:18 ON 30 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 11:22:04 ON 30 JUL 2009
L1             STRUCTURE UPLOADED
L2           2 S L1 SAM
L3          30 S L1 FULL

     FILE 'CA' ENTERED AT 11:22:29 ON 30 JUL 2009
L4           1 S L3

     FILE 'MARPAT' ENTERED AT 11:22:40 ON 30 JUL 2009
L5          14 S L3 FULL

     FILE 'REGISTRY' ENTERED AT 11:24:23 ON 30 JUL 2009
L6             STRUCTURE UPLOADED
L7           1 S L6 SAM
L8           4 S L6 FULL
```

```
     FILE 'CA' ENTERED AT 11:24:53 ON 30 JUL 2009
L9            1 S L8

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\13599002.str
```





```
chain nodes :
11  12  13  14
ring nodes :
1  2  3  4  5  6  7  8  9  10
chain bonds :
6-13  10-11  11-12  13-14
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-10  4-5  5-6  7-8  8-9  9-10
exact/norm bonds :
10-11  11-12  13-14
exact bonds :
6-13
normalized bonds :
```

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:N,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom

L10 STRUCTURE UPLOADED

=> d l109
L109 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 N,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l10 full
FULL SEARCH INITIATED 11:26:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5502 TO ITERATE

100.0% PROCESSED 5502 ITERATIONS 26 ANSWERS
SEARCH TIME: 00.00.01

L11 26 SEA SSS FUL L10

=> file ca

=> s l11

L12 1 L11

=> d ibib

L12 ANSWER 1 OF 1 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:386931 CA
TITLE: Preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders
INVENTOR(S): Ahmed, Mahmood; Johnson, Christopher Norbert; Miller, Neil Derek; Trani, Giancarlo; Witty, David R.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Witty, David R
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095346	A1	20051013	WO 2005-GB1106	20050324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730112	A1	20061213	EP 2005-729157	20050324
EP 1730112	B1	20080903		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007530648	T	20071101	JP 2007-505618	20050324
AT 407120	T	20080915	AT 2005-729157	20050324
ES 2313319	T3	20090301	ES 2005-729157	20050324
US 20070191345	A1	20070816	US 2006-599002	20060918

PRIORITY APPLN. INFO.: GB 2004-7025 A 20040329
WO 2005-GB1106 W 20050324
OTHER SOURCE(S): CASREACT 143:386931; MARPAT 143:386931
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:21:18 ON 30 JUL 2009)

FILE 'REGISTRY' ENTERED AT 11:22:04 ON 30 JUL 2009
L1 STRUCTURE UPLOADED

```
L2             2 S L1 SAM
L3            30 S L1 FULL

     FILE 'CA' ENTERED AT 11:22:29 ON 30 JUL 2009
L4             1 S L3

     FILE 'MARPAT' ENTERED AT 11:22:40 ON 30 JUL 2009
L5            14 S L3 FULL

     FILE 'REGISTRY' ENTERED AT 11:24:23 ON 30 JUL 2009
L6               STRUCTURE UPLOADED
L7             1 S L6 SAM
L8             4 S L6 FULL

     FILE 'CA' ENTERED AT 11:24:53 ON 30 JUL 2009
L9             1 S L8

     FILE 'REGISTRY' ENTERED AT 11:25:14 ON 30 JUL 2009
L10              STRUCTURE UPLOADED
L11           26 S L10 FULL

     FILE 'CA' ENTERED AT 11:26:06 ON 30 JUL 2009
L12            1 S L11

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y
INTERNATIONAL LOGOFF AT 11:26:19 ON 30 JUL 2009
```